• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

    5/12/23 6:32:51 PM ET
    $BWV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BWV alert in real time by email

    CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress. Blue Water Biotech is a biological and pharmaceutical technology company developing multiple preclinical vaccine candidates across various infectious diseases and owns the FDA-approved benign hyperplasia ("BPH") asset, ENTADFI®.

    "Blue Water's recent growth is highlighted by our acquisition of ENTADFI®, as well as our subsequent rebranding initiative and name change to reflect our transition into a commercial-stage biotechnology company," said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water. "We believe this product has the potential to be transformative for men suffering from BPH, and we are confident that our experienced management team will be the driving force behind ENTADFI®'s anticipated success. We are also excited to bring in an approved asset to support the operations for our preclinical vaccine programs, including our Streptococcus pneumoniae vaccine candidate that is progressing towards clinical trials in the near term."

    Q1 2023 and Recent Corporate Developments

    • In April 2023, Blue Water announced the acquisition of ENTADFI®, an FDA-approved treatment for BPH that counteracts negative sexual side effects seen in men on alternative BPH therapies.
      • Under the asset purchase agreement, Blue Water purchased ENTADFI® for a total consideration of up to $100 million, with $20 million upfront, paid in defined tranches through September 2024, and the possibility of an additional $80 million based on predetermined annual sales milestones.
      • Following this acquisition, Blue Water announced in April 2023 that the Company changed its corporate name to Blue Water Biotech, Inc. to reflect its transition into a commercial-stage company.
    • In February 2023, Blue Water announced the appointment of seasoned commercial operations leader Frank Jaeger as Senior Vice President of Marketing and Business Development. Blue Water will leverage Mr. Jaeger's experience, specifically in Men's Health through his experience with JATENZO® and AndroGel 1.62%, in the official launch of ENTADFI® and its anticipated success within the BPH market.
    • Throughout the first quarter of 2023 and beyond, Blue Water management presented its corporate overview and Company updates at key investor, financial, and scientific conferences to highlight the value story of the Blue Water pipeline and target leaders within the investment community.
      • In January 2023, Blue Water presented an overview of its vaccine candidate pipeline and progress at Biotech Showcase 2023 during the 41st annual J.P. Morgan Healthcare Conference Week in San Francisco, California. In addition, Blue Water management participated in the World Vaccine Congress in Washington D.C. in April 2023.
      • To promote ENTADFI® and connect with key leaders in the urology space, Blue Water management sponsored a booth at the American Urological Association Annual Meeting 2023 in Chicago, Illinois.
    • In January 2023, Blue Water announced the appointment of seasoned public market and private equity investment leader, Timothy Ramdeen, to its board of directors. Mr. Ramdeen has nearly a decade of experience in private equity and hedge fund investing, capital markets, and company formation.

    Q1 2023 and Recent Vaccine Candidate Developments

    • In February 2023, Blue Water announced a partnership with AbVacc, Inc. ("AbVacc") for the joint development of novel vaccine candidates targeting monkeypox and Marburg virus disease, among others. The vaccine candidates will utilize Blue Water's norovirus shell and protrusion virus-like particle platform, which allows for the presentation of multiple antigens on the surface of either the S or P particle of a norovirus backbone. Under this partnership, Blue Water and AbVacc will work collaboratively to identify appropriate antigens to use within this platform and will work toward clinical development of vaccine candidates.
    • In March 2023, Blue Water signed a sponsored research agreement with The University of Texas Health Science Center at San Antonio to initiate a non-human primate study for Blue Water's live attenuated, orally delivered Chlamydia vaccine, BWV-401. In this study, non-human primates will be vaccinated with BWV-401 and subsequently challenged against Chlamydia to validate they hypothesis that this vaccine is both safe and efficacious in a human-like model.

    Q1 2023 Financial Highlights

    • Cash Position: Cash was $20.3 million as of March 31, 2023, as compared to $25.8 million as of December 31, 2022. The decrease was primarily due to an increase in various business activities to support company growth, as well as increased research and development activities.
    • Research and Development Expenses: For the three months ended March 31, 2023, research and development expenses increased by approximately $0.6 million compared to the same period in 2022. The increase was primarily attributable to an increase in preclinical development activities of approximately $0.3 million mainly related to BWV-101 and BWV-201, and an increase in research and development personnel costs.
    • General and Administrative Expenses: For the three months ended March 31, 2023, general and administrative expenses increased by $0.2 million compared to the same period in 2022. The increase was mainly due to an increase in professional fees and an increase in various business activities related to company growth and development, such as business advisory services, travel, and rent expenses. These increases were offset by a decrease in employee compensation, as well as a non-recurring expense in the three months ended March 31, 2022 to early terminate an agreement with an underwriter, with no similar expense in the current period.
    • Other Income: Other income relates to the change in fair value of the contingent warrant liability, which was incurred at the close of the Company's private placements in April and August 2022. There was no other income or expense during the three months ended March 31, 2022.
    • Net Loss: Net loss was approximately $2.8 million for the three months ended March 31, 2023, as compared to $2.1 million for the same period in 2022. The increase is primarily due to research and development of preclinical vaccine candidates.



    BLUE WATER BIOTECH, INC.

    Condensed Balance Sheets

      March 31,

    2023
      December 31,

    2022
     
    ASSETS  (Unaudited)    
    Current assets      
    Cash $20,255,803  $25,752,659 
    Restricted cash  1,000,000   — 
    Prepaid expenses and other current assets  780,173   469,232 
    Deferred offering costs  366,113   — 
    Receivable from related parties  70,302   35,850 
    Total current assets  22,472,391   26,257,741 
             
    Prepaid expenses, long-term  15,500   38,617 
    Property and equipment, net  14,210   14,089 
    Total assets $22,502,101  $26,310,447 
             
    LIABILITIES AND STOCKHOLDERS' EQUITY        
    Current liabilities        
    Accounts payable $1,503,262  $1,499,296 
    Accrued expenses  1,292,951   2,409,128 
    Contingent warrant liability  12,406   14,021 
    Total current liabilities  2,808,619   3,922,445 
             
    Total liabilities  2,808,619   3,922,445 
             
    Commitments and Contingencies        
             
    Stockholders' equity        
    Preferred stock, $0.00001 par value, 10,000,000 shares authorized at March 31, 2023 and December 31, 2022; 0 shares issued and outstanding at March 31, 2023 and December 31, 2022  —    —  
    Common stock, $0.00001 par value, 250,000,000 shares authorized at March 31, 2023 and December 31, 2022; 16,371,597 and 15,724,957 shares issued at March 31, 2023 and December 31, 2022, respectively; 15,879,230 and 15,265,228 shares outstanding at March 31, 2023 and December 31, 2022, respectively  164   157 
    Additional paid-in-capital  42,516,726   42,331,155 
    Treasury stock, at cost; 492,367 and 459,729 shares of common stock at March 31, 2023 and December 31, 2022, respectively  (600,264)  (566,810) 
    Accumulated deficit  (22,223,144)  (19,376,500)
    Total stockholders' equity  19,693,482   22,388,002 
    Total liabilities and stockholders' equity $22,502,101  $26,310,447 

      



    BLUE WATER BIOTECH, INC.


    Condensed Statements of Operations

    (Unaudited)

      Three Months Ended

    March 31, 
    2023
      Three Months Ended

    March 31, 
    2022
     
    Operating expenses      
    General and administrative $1,766,022   $1,615,569 
    Research and development  1,082,237    455,092 
    Total operating expenses  2,848,259    2,070,661 
    Loss from operations  (2,848,259)   (2,070,661)
    Other income        
    Change in fair value of contingent warrant liability  (1,615)   — 
    Total other income  (1,615)   — 
    Net loss $(2,846,644)  $(2,070,661)
    Cumulative preferred stock dividends  —    96,359 
    Net loss applicable to common stockholders  (2,846,644)   (2,167,020)
             
    Net loss per share attributable to common stockholders, basic and diluted $(0.18)  $(0.34)
             
    Weighted average number of common shares outstanding, basic and diluted  15,910,415    6,339,435 
              

    About ENTADFI®

    ENTADFI® is an oral, once daily treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, offering a more effective treatment option compared to other available therapies. Clinical trials have shown that ENTADFI® is more effective in treating BPH symptoms, including urinary frequency, urgency, weak stream, and difficulty initiating or maintaining urination, compared to finasteride monotherapy. Additionally, ENTADFI® has demonstrated a favorable safety profile, with fewer adverse sexual side effects compared to finasteride. ENTADFI® reduces potential for adverse sexual side effects, making it a preferred choice for men seeking relief from BPH symptoms without compromising their sexual health. ENTADFI® has received FDA approval for the indication of initiating treatment of the signs and symptoms of BPH in men with an enlarged prostate for up to 26 weeks. More information about BPH and full ENTADFI® prescribing information can be found on the product website at https://entadfipatient.com/.

    About Blue Water Biotech

    Blue Water Biotech, Inc. is a biological and pharmaceutical technology company focused on developing and providing transformational therapies to address significant health challenges globally. Headquartered in Cincinnati, OH, the Company holds the rights to proprietary technology developed at the University of Oxford, Cincinnati Children's Hospital Medical Center, St. Jude Children's Hospital, and The University of Texas Health Science Center at San Antonio. Blue Water is developing a Streptococcus pneumoniae vaccine candidate, designed to specifically prevent highly infectious middle ear infections, known as acute otitis media (AOM), in children, and prevention of pneumonia in the elderly. The Company is also developing a universal flu vaccine that will provide protection from all virulent strains in addition to licensing a novel norovirus (NoV) S&P nanoparticle versatile virus-like particle (VLP) vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, among others. Additionally, the Company is developing a Chlamydia vaccine candidate with UT Health Science Center San Antonio to prevent infection and reduce the need for antibiotic treatment associated with contracting Chlamydia disease. Outside of its vaccine franchise, Blue Water owns ENTADFI®, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. This combination allows men to receive treatment for their symptoms of BPH without the negative sexual side effects typically seen in patients on finasteride alone. For more information about Blue Water, visit www.bwbioinc.com.

    Forward-Looking Statements

    Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Blue Water's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to Blue Water's ability to realize the benefits of its acquisition of ENTADFI®, risks related to BWV's ability to expand its business scope and its ability to commercialize ENTADFI®, risks related to the development of Blue Water's vaccine candidates; the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any vaccine under development, there are significant risks in the development, regulatory approval and commercialization of new products. Blue Water does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Blue Water's Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on March 9, 2023 and periodic reports filed with the SEC on or after the date thereof. All of Blue Water's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

    Media Contact Information:

    Blue Water Media Relations

    Telephone: (646) 942-5591

    Email: [email protected]

    Investor Contact Information:

    Blue Water Investor Relations

    Email: [email protected] 



    Get the next $BWV alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BWV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BWV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders

      CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (NASDAQ:BWV) ("Onconetix" or the "Company") today issued the following shareholder letter from the Company's Chief Executive Officer, Dr. Neil Campbell. To Our Valued Shareholders, As 2023 draws to a close, I am eager to share with you the significant strides Onconetix, Inc. (formerly Blue Water Biotech, Inc.) has made in our journey towards becoming a leader in oncology. This past quarter has been transformative, marked by strategic shifts and notable achievements, all aimed at enhancing the value we bring to you as our shareholders. To reflect our recent achievements and renewed oncology focus, we have rebranded as Onconet

      12/19/23 7:00:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

      CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the "Transaction"), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics and services for the treatment of cancer. The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix. With the tran

      12/18/23 7:00:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Biotech Signs Non-Binding Term Sheet to Acquire a Commercial Stage Oncology Company

      CINCINNATI, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company"), today announced the execution of a non-binding term sheet regarding the acquisition of a private commercial stage oncology biotechnology company (the "Proposed Transaction"). This latest announcement is part of the Company's new business strategy focusing on oncology. The Company plans to commercialize therapeutics, diagnostics and clinician services, which will serve as the foundation for the Company's future operations. The Proposed Transaction furthers a shift in business strategy driven by BWB's decision to align with both the market value drivers provided by its new oncolog

      11/2/23 7:00:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BWV
    SEC Filings

    See more
    • SEC Form S-1 filed by Blue Water Biotech Inc.

      S-1 - Onconetix, Inc. (0001782107) (Filer)

      2/14/24 5:06:02 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Blue Water Biotech Inc.

      PRE 14A - Onconetix, Inc. (0001782107) (Filer)

      2/14/24 5:04:25 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Biotech Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Onconetix, Inc. (0001782107) (Filer)

      2/13/24 8:24:20 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BWV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Singh Ajit

      3 - Onconetix, Inc. (0001782107) (Issuer)

      2/16/24 4:05:21 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Meier Thomas

      3 - Onconetix, Inc. (0001782107) (Issuer)

      2/16/24 4:05:11 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Schiess Ralph claimed ownership of 269,749 shares (SEC Form 3)

      3 - Onconetix, Inc. (0001782107) (Issuer)

      1/3/24 4:05:49 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BWV
    Leadership Updates

    Live Leadership Updates

    See more
    • Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

      CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO, effective immediately. Dr. Campbell has also joined the Company's board of directors. Dr. Campbell has more than 35 years of experience with public and private companies focused on biopharmaceuticals, health technologies, nanotechnologies, artificial intelligence and super-computing. He has held leadership positions with IGEN International, now Roche; Celera Genomics; and Abbott

      10/10/23 9:00:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer

      CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology company spanning multiple sectors, today announced the appointment of Jay Newmark, M.D., MBA as the Company's Chief Medical Officer. Dr. Newmark is a board-certified urologist with over 30 years of experience managing Men's Health issues, including benign prostatic hyperplasia ("BPH"). Blue Water currently owns ENTADFI®, an FDA-approved treatment for BPH that counteracts negative sexual side effects seen in men on alternative BPH therapies. Dr. Newmark's appointment will support Blue Water's upcoming launch of ENTADFI® and he will work closely with Blue Water management

      4/26/23 3:44:02 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Vaccines Appoints Seasoned Commercial Operations Leader Frank Jaeger as Senior Vice President of Marketing and Business Development

      CINCINNATI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. ("BWV" or "Blue Water Vaccines" or the "Company"), today announced the appointment of Frank Jaeger, seasoned commercial operations and business development executive, as Senior Vice President of Marketing and Business Development. Mr. Jaeger brings over 25 years of biopharmaceutical experience to the BWV team, from start-up to large global pharma with significant pre-launch, launch, and in-market commercialization experience. His background in R&D, Medical Affairs, Business Development, and throughout Commercial Operations provides a broad world view and an understanding of varying perspectives. Mr. Jaeger has a wide r

      2/6/23 10:15:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BWV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Blue Water Biotech Inc. (Amendment)

      SC 13G/A - Onconetix, Inc. (0001782107) (Subject)

      1/26/24 6:01:11 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Blue Water Biotech Inc. (Amendment)

      SC 13G/A - Onconetix, Inc. (0001782107) (Subject)

      1/2/24 1:13:20 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Blue Water Biotech Inc.

      SC 13G - Onconetix, Inc. (0001782107) (Subject)

      12/27/23 6:34:55 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BWV
    Financials

    Live finance-specific insights

    See more
    • Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™

      CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (NASDAQ:BWV) ("BWB" or the "Company") today announced the acquisition of Proteomedix AG, a private, commercial-stage diagnostics oncology company (the "Transaction"), and introduced a new name for the combined Company: Onconetix, Inc. The Transaction reflects a transformation of the business to one focused on the research, development and commercialization of proprietary science and technologies for therapeutics, diagnostics and services for the treatment of cancer. The acquisition of Proteomedix for all stock consideration provides its shareholders with an initial 19.9% ownership stake of Onconetix. With the tran

      12/18/23 7:00:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Biotech Reports First Quarter 2023 Financial Results and Recent Business Highlights

      CINCINNATI, May 12, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. ("Blue Water" or the "Company"), a biotechnology company spanning multiple sectors, today announced its financial results for the quarter ended March 31, 2023 and provided an update on recent business developments and Company progress. Blue Water Biotech is a biological and pharmaceutical technology company developing multiple preclinical vaccine candidates across various infectious diseases and owns the FDA-approved benign hyperplasia ("BPH") asset, ENTADFI®. "Blue Water's recent growth is highlighted by our acquisition of ENTADFI®, as well as our subsequent rebranding initiative and name change to reflect our transiti

      5/12/23 6:32:51 PM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset

      Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference call Today, April 20th, at 8:30am EDT to Discuss Asset Purchase and Company Transformation CINCINNATI, April 20, 2023 (GLOBE NEWSWIRE) --  Blue Water Vaccines Inc. ("BWV" or "Blue Water" or the "Company"), today announced the signing of an Asset Purchase Agreement (the "Agreement") with Veru Inc. ("Veru") for the purchase of ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia ("BPH") that counteracts negative sexual side effects seen in men on alternative BPH therapies. Unde

      4/20/23 7:30:00 AM ET
      $BWV
      Biotechnology: Pharmaceutical Preparations
      Health Care